Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer.
Gürbüz M, Akkuş E, Sakin A, Urvay S, Demiray AG, Şahin S, Şakalar T, Erol C, Şendur MAN, Şahin AB, Çubukçu E, Güven DC, Kılıçkap S, Ergün Y, Uncu D, Turhal NS, Üskent N, Yeşil Çınkır H, Demir A, Acar R, Karadurmuş N, Türker S, Altınbaş M, Karaoğlan M, Çay Şenler F. Gürbüz M, et al. Among authors: sakalar t. Tumori. 2021 Oct;107(5):416-423. doi: 10.1177/0300891620969823. Epub 2020 Nov 9. Tumori. 2021. PMID: 33167790
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U; Turkish Oncology Group. Esin E, et al. Among authors: sakalar t. Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143. doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30. Cancer Chemother Pharmacol. 2019. PMID: 30377778
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group Study.
Yildiz B, Kucukarda A, Gokyer A, Gokcen Demiray A, Paydas S, Pinar Aral I, Gumusay O, Bilici A, Akdeniz N, Bahceci A, Demir H, Esin E, Üyeturk U, Nihat Okten I, Erturk I, Turk HM, Topaloglu US, Basoglu T, Serdar Turhal N, Yesil Cinkir H, Menekse S, Cakmak Y, Urun Y, Acar R, Kut E, Dal P, Sakalar T, Halit Aktepe O, Karadurmus N, Bilici A. Yildiz B, et al. Among authors: sakalar t. J BUON. 2020 Mar-Apr;25(2):1130-1135. J BUON. 2020. PMID: 32521916 Free article.
Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.
Bekir Hacioglu M, Kostek O, Karabulut S, Tastekin D, Sezgin Goksu S, Alandag C, Akagunduz B, Bilgetekin I, Caner B, Bilgehan Sahin A, Yildiz B, Kose F, Kaplan MA, Gulmez A, Dogan E, Can Guven D, Gurbuz M, Ergun Y, Karaagac M, Gokcen Demiray A, Turker S, Sakalar T, Ozkul O, Telli TA, Sahin S, Kilickap S, Bilici A, Erdogan B, Cicin I. Bekir Hacioglu M, et al. Among authors: sakalar t. J BUON. 2020 Jul-Aug;25(4):1897-1903. J BUON. 2020. PMID: 33099930 Free article.
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Bilgin B, Sendur MAN, Yucel S, Celik E, Ozyukseler DT, Ayhan M, Basoglu T, Ilhan A, Akdeniz N, Gulmez A, Dogan I, Aktas BY, Gurbuz M, Koca S, Paydas S, Tatli AM, Cinkir HY, Alan O, Erol C, Hizal M, Kut E, Menevse S, Sakalar T, Taskaynatan H, Deniz GI, Karaagac M, Avci O, Sen E, Karatas F, Akinci MB, Dede DS, Demir A, Demirkazık A, Oksuzoglu B, Kilickap S, Yumuk F, Yalcin B. Bilgin B, et al. Among authors: sakalar t. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6. Epub 2021 Jan 12. J Cancer Res Clin Oncol. 2021. PMID: 33433657
Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group.
Gürbüz M, Akkuş E, Sakin A, Urvay S, Demiray AG, Şahin S, Şakalar T, Erol C, Şendur MAN, Şahin AB, Çubukçu E, Güven DC, Kılıçkap S, Ergün Y, Uncu D, Turhal NS, Üskent N, Çınkır HY, Demir A, Acar R, Karadurmuş N, Türker S, Altınbaş M, Karaoğlan M, Şenler FÇ. Gürbüz M, et al. Among authors: sakalar t. J Gastrointest Cancer. 2022 Jun;53(2):282-288. doi: 10.1007/s12029-021-00594-1. Epub 2021 Feb 4. J Gastrointest Cancer. 2022. PMID: 33538958
48 results